QRG Capital Management Inc. Buys 9,632 Shares of Zoetis Inc. $ZTS

QRG Capital Management Inc. increased its stake in Zoetis Inc. (NYSE:ZTS) by 14.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 74,760 shares of the company’s stock after purchasing an additional 9,632 shares during the quarter. QRG Capital Management Inc.’s holdings in Zoetis were worth $8,837,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ZTS. Global Wealth Strategies & Associates bought a new position in shares of Zoetis in the fourth quarter valued at approximately $25,000. Prosperity Bancshares Inc bought a new stake in shares of Zoetis during the 4th quarter worth $25,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis during the 4th quarter worth $30,000. Root Financial Partners LLC grew its stake in Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. Finally, KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis in the 3rd quarter valued at $31,000. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research analyst reports. JPMorgan Chase & Co. cut their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Stifel Nicolaus lowered their price target on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Barclays cut their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, UBS Group lowered their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $126.92.

Zoetis Price Performance

Shares of Zoetis stock opened at $74.73 on Friday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a fifty-two week low of $71.47 and a fifty-two week high of $161.77. The firm has a fifty day moving average price of $84.04 and a two-hundred day moving average price of $109.40. The company has a market cap of $31.33 billion, a PE ratio of 12.39, a price-to-earnings-growth ratio of 1.17 and a beta of 0.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts expect that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…

Insider Activity at Zoetis

In other news, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The stock was purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 11,650 shares of company stock worth $886,384 over the last three months. Company insiders own 0.22% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.